These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37914609)

  • 1. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
    Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM
    Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
    Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
    Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
    Fiala O; Buti S; Bamias A; Massari F; Pichler R; Maruzzo M; Grande E; De Giorgi U; Molina-Cerrillo J; Seront E; Calabrò F; Myint ZW; Facchini G; Kopp RM; Berardi R; Kucharz J; Vitale MG; Pinto A; Formisano L; Büttner T; Messina C; Monteiro FSM; Battelli N; Kanesvaran R; Büchler T; Kopecký J; Santini D; Giudice GC; Porta C; Santoni M
    Target Oncol; 2024 Jul; 19(4):587-599. PubMed ID: 38704759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
    Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
    Clin Genitourin Cancer; 2024 Jun; 22(3):102078. PubMed ID: 38631104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.
    Bolek H; Yekedüz E; Ürün Y
    Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
    Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L
    Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
    Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
    World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
    Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
    Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
    Manneh R; Lema M; Carril-Ajuria L; Ibatá L; Martínez S; Castellano D; de Velasco G
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world data on IO-based therapy for metastatic renal cell carcinoma.
    Stühler V; Herrmann L; Rausch S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3249-3258. PubMed ID: 35907009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
    Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
    Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
    Massari F; Mollica V; Fiala O; De Giorgi U; Kucharz J; Vitale MG; Molina-Cerrillo J; Facchini G; Seront E; Lenci E; Bourlon MT; Carrozza F; Pichler R; Lolli C; Myint ZW; Kanesvaran R; Torniai M; Rescigno P; Gomez de Liaño A; Zakopoulou R; Buti S; Porta C; Grande E; Santoni M
    Eur Urol Oncol; 2024 Oct; 7(5):1123-1131. PubMed ID: 38575409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
    Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
    Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
    Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Bassanelli M; Merler S; Messina C; Küronya Z; Mosca A; Bhuva D; Vau N; Incorvaia L; Rebuzzi SE; Roviello G; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Montironi R; Battelli N; Porta C
    Target Oncol; 2023 Jul; 18(4):559-570. PubMed ID: 37369815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
    Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
    Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).
    Ciccarese C; Büttner T; Cerbone L; Zampiva I; Monteiro FSM; Basso U; Pichler M; Vitale MG; Fiala O; Roviello G; Kopp RM; Carrozza F; Pichler R; Grillone F; Calabuig EP; Zeppellini A; Küronya Z; Galli L; Facchini G; Sunela K; Mosca A; Molina-Cerrillo J; Spinelli GP; Ansari J; Scala A; Mollica V; Grande E; Buti S; Kanesvaran R; Zakopoulou R; Bamias A; Rizzo M; Massari F; Iacovelli R; Santoni M
    Int J Cancer; 2024 Dec; 155(11):2036-2046. PubMed ID: 39243397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.